INT'L GROUP(SZ:000411)2025-04-24 09:00Financial Performance - The company's operating revenue for 2024 reached ¥33,351,653,828.95, representing a 4.05% increase compared to ¥32,052,121,586.44 in 2023[20]. - The net profit attributable to shareholders for 2024 was ¥525,522,107.14, a 7.53% increase from ¥488,732,096.82 in 2023[20]. - The net profit after deducting non-recurring gains and losses was ¥509,880,346.81, which is a 25.74% increase from ¥405,498,097.75 in 2023[20]. - The total assets at the end of 2024 amounted to ¥14,632,477,002.42, reflecting a 5.20% increase from ¥13,908,856,860.12 at the end of 2023[20]. - The company's basic earnings per share for 2024 was ¥1.02, down 6.42% from ¥1.09 in 2023[20]. - The company reported a cash flow from operating activities net amount of ¥410,324,781.82, a decrease of 3.52% compared to ¥425,313,727.37 in 2023[20]. - The company achieved a gross margin of 6.63% in pharmaceutical sales, with a slight increase of 0.25% year-on-year[65]. - The total operating revenue for 2024 reached ¥33.35 billion, representing a 4.05% increase from ¥32.05 billion in 2023[64]. - The pharmaceutical wholesale sector accounted for ¥29.93 billion, or 89.75% of total revenue, with a year-on-year growth of 2.90%[65]. - The pharmaceutical retail sector saw a significant increase of 15.46%, generating ¥3.18 billion, which is 9.53% of total revenue[64]. Dividends and Shareholder Engagement - The company plans to distribute a total cash dividend of 200 million CNY to all shareholders, with no stock dividends issued[4]. - The company implemented a stable cash dividend policy, with a cash dividend of 200 million yuan (including tax), representing 38.06% of the net profit attributable to shareholders[165]. - The cash dividend per 10 shares is set at 3.83 yuan (including tax), based on a total share capital of 521,892,509 shares[165]. - The total cash dividend amount, including other methods, is 200 million yuan, which accounts for 100% of the total profit distribution[165]. - The company ensures that minority shareholders have sufficient opportunities to express their opinions and that their legal rights are fully protected[164]. - The participation ratio for the 2024 first extraordinary shareholders' meeting was 73.16%[130]. - The participation ratio for the 2023 annual shareholders' meeting was 73.14%[130]. - The participation ratio for the 2024 second extraordinary shareholders' meeting was 73.26%[130]. Corporate Governance and Management - The financial report is guaranteed to be true, accurate, and complete by the company's board and management[4]. - The company has a strong leadership team with members having backgrounds in finance, law, and strategic management, enhancing its operational capabilities[137]. - The company emphasizes compliance and legal oversight, with dedicated roles for legal and risk management within its executive team[141]. - The company has appointed independent directors with significant academic and industry experience, contributing to its governance and strategic direction[139]. - The board of directors held a total of 13 meetings during the reporting period, with all resolutions reported to the Shenzhen Stock Exchange[147]. - The independent directors provided valuable professional advice on internal control, management system construction, and major decision-making[152]. - The company has established a robust incentive mechanism for senior management, aligning their performance with company goals[169]. - The management team is evaluated based on performance metrics directly linked to their compensation, promoting accountability and performance improvement[169]. Risk Management and Compliance - The company emphasizes the importance of risk awareness regarding forward-looking statements related to development strategies and future plans[4]. - The company is committed to maintaining high standards in quality and compliance, as indicated by the roles of its quality management team[135]. - The company adheres to strict quality management protocols to mitigate risks associated with product quality issues, which could lead to financial and reputational damage[119]. - The company is focused on enhancing its governance structure and talent acquisition strategies to optimize its workforce and improve operational efficiency[114]. - The company is committed to fulfilling all promises made during the acquisition process, with accountability for any breaches[185]. - The company will ensure compliance with relevant laws and regulations regarding related transaction decision-making procedures and information disclosure obligations[187]. Strategic Development and Market Position - The company is positioned in the pharmaceutical distribution industry, which is undergoing modernization and digital transformation, driven by increasing consumer demand and regulatory reforms[29]. - The company aims to enhance its market share in pharmaceuticals and expand its professional marketing efforts, targeting a leading position in every market segment within the province[111]. - The company plans to accelerate mergers and acquisitions, focusing on top-ranked pharmaceutical wholesale enterprises with a scale of over several billion in economically developed regions[115]. - The company is advancing its digital transformation, aiming to fully utilize data in its operations and enhance organizational efficiency[60]. - The company is focusing on high-value-added areas and exploring partnerships with commercial insurance to broaden payment channels and enhance customer service[118]. Community Engagement and Social Responsibility - The company is committed to social responsibility and sustainable development, aiming to create value for shareholders while contributing positively to society[111]. - The company donated 300,000 yuan to support sustainable development in rural areas, contributing to poverty alleviation efforts[181]. - The company has actively engaged in over 30 volunteer activities, involving 563 participants, to promote social responsibility and community support[180]. - The company is involved in strategic partnerships to enhance its service offerings and community impact[182]. Investments and Acquisitions - The company acquired 51% of Shenzhou Yintianhua Pharmacy and 100% of Hangzhou Guangji Huanlong Trading Co., expanding its market presence[70]. - The company has established a comprehensive provincial distribution network with six logistics centers and over 200 retail stores across 11 cities in Zhejiang province[40][42]. - The company initiated the construction of the Zhejiang Yinte Shitang Pharmaceutical Industrial Park, covering an area of 119 acres, to enhance logistics and industry incubation[59]. - The company is developing an end-to-end cold chain logistics system for vaccines, aiming for real-time monitoring and precise regulation[74]. Digital Transformation and Technology - The company is advancing its digital transformation to improve logistics efficiency and service quality through a comprehensive information management system[49]. - The government is promoting digital transformation in the pharmaceutical industry, emphasizing the integration of AI and big data technologies[34]. - The company has developed a digital energy monitoring platform to automate energy consumption data collection and analysis, enhancing operational efficiency[177]. Employee Management and Development - The total number of employees at the end of the reporting period is 3,072, with 1,695 in sales and 165 in finance[158]. - The company has established a training plan to enhance the skills of its workforce, focusing on high-quality talent development[161]. - The company has implemented a salary policy that links compensation to performance and strategic business support[160]. Financial Management and Internal Controls - The company has implemented an effective internal control system, ensuring compliance with laws and regulations, and enhancing operational efficiency[170]. - The internal control measures have met the expected objectives, safeguarding the interests of the company and its shareholders[170]. - The company maintained effective internal control over financial reporting as of December 31, 2024, according to the internal control audit report[174].